Firm-Level Exposure to Epidemic Diseases: COVID-19, SARS, and H1N1
The Review of Financial Studies · 20.11.2023 · 36 (12) · 4919-4964
DOI: 10.1093/rfs/hhad044 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Review of Financial Studies, online erschienen am 17.05.2023. Verfasst von Tarek A Hassan und 4 weiteren Autor:innen. Die Arbeit wurde bisher 165-mal zitiert (Crossref) und nennt 70 Literaturangaben.
Abstract (Originalsprache)
We construct text-based measures of the primary concerns listed firms associated with the spread of COVID-19 and other epidemic diseases. We identify which firms perceive to lose or gain from a given epidemic and textually decompose the epidemic’s effect on the firm’s demand and supply. We find that the effects of COVID-19 manifest as a simultaneous shock to demand and supply, with both shocks affecting firms’ market valuations in equal measure on average. By contrast, demand-related impacts appear more important in accounting for the observed collapse in firm-level investment during the COVID-19 crisis. Authors have furnished an Internet Appendix, which is available on the Oxford University Press Web site next to the link to the final published paper online
Zitieren
APA
Hassan, T. A., Hollander, S., Lent, L. V., Schwedeler, M., & Tahoun, A. (2023). Firm-Level Exposure to Epidemic Diseases: COVID-19, SARS, and H1N1. The Review of Financial Studies, 36(12), 4919-4964. https://doi.org/10.1093/rfs/hhad044
Vancouver
Hassan TA, Hollander S, Lent LV, Schwedeler M, Tahoun A. Firm-Level Exposure to Epidemic Diseases: COVID-19, SARS, and H1N1. The Review of Financial Studies. 2023;36(12):4919-4964. doi:10.1093/rfs/hhad044
BibTeX
@article{Hassan2023,
author = {Hassan, Tarek A and Hollander, Stephan and Lent, Laurence van and Schwedeler, Markus and Tahoun, Ahmed},
title = {Firm-Level Exposure to Epidemic Diseases: COVID-19, SARS, and H1N1},
journal = {The Review of Financial Studies},
year = {2023},
volume = {36},
number = {12},
pages = {4919--4964},
doi = {10.1093/rfs/hhad044}
}
EUVIMED